Amphenol Climbs on Trexon Acquisition
Amphenol Corporation (NYSE: APH) shares gained ground Monday on announcing a definitive agreement to acquire Trexon for approximately $1 billion in cash, subject to customary post-closing adjustments. Trexon is a leading provider of high-reliability interconnect and cable assemblies primarily for the defense market. Headquartered in Boston, and with facilities in the U.S. and the U.K., Trexon is expected to have 2025 sales and EBITDA margins of approximately $290 million and 26%, respectively.“We are extremely pleased to announce this agreement to add Trexon to the Amphenol family,” said Amphenol CEO Adam Norwitt. “Trexon’s unique portfolio of high-reliability cable assembly products will be highly complementary to our existing offerings in the defense market. We look forward to working in partnership with Trexon’s experienced management team to deliver additional high-technology solutions to our customers post closing.”The transaction is subject to certain regulatory approvals and other customary closing conditions. Amphenol will finance the transaction with cash on hand and expects to close in the fourth quarter of 2025. The acquisition will be included in the Harsh Environment Solutions segment and is expected to be accretive to Amphenol’s earnings per share in the first-year post closing.APH shares began Monday trading up $1.74, or 1.6%, to $110.95.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


